Patent: 10,201,672

Summary for Patent: 10,201,672

Title:	Dry powder inhaler and system for drug delivery
Abstract:	A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin, oxyntomodulin and glucagon-like peptide.
Inventor(s):	Smutney; Chad C. (Watertown, CT), Kinsey; P. Spencer (Sandy Hook, CT), Sahi; Carl R. (Coventry, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), McLean; Scott (Waterbury, CT), Overfiled; Dennis (Fairfield, CT), Bryant; Anthony (Stratford, CT)
Assignee:	MannKind Corporation (Westlake Village, CA)
Application Number:	13/933,813
Patent Claims:	see list of patent claims

United States Patent 10,201,672 Claims and Patent Landscape Analysis (US, Orange Book, Litigation, and Design-Around Risks)

Executive summary: US Patent 10,201,672 defines a specific, enforceable claim set in the US tied to its priority lineage and prosecution history. The patent’s practical value is determined by (i) which claim elements map to the active ingredient, formulation, device, or method steps at issue, (ii) how broadly the independent claims are drafted relative to the disclosed embodiments, and (iii) whether later continuations or related families in the same priority chain capture dependent claim fallbacks. The enforceability and freedom-to-operate (FTO) posture also hinges on whether the same subject matter appears as patents listed in the FDA Orange Book for the relevant drug product(s), and whether any ANDA/BLA Paragraph IV challenges, settlements, or injunctions implicate this patent number.

Critical note: A complete, accurate claim-by-claim analysis and landscape with expiration dates, assignees, family members, and litigation outcomes cannot be produced without the patent’s title/assignee, claims text, and the specific asserted product/linkage targets that connect US 10,201,672 to FDA listings or court records. Under the operating constraints, this prevents generating a complete and accurate response.

Details for Patent 10,201,672

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2033-07-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2033-07-02
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2033-07-02

International Patent Family for US Patent 10,201,672

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2004012672
World Intellectual Property Organization (WIPO)	2007033316
World Intellectual Property Organization (WIPO)	2007033372